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Reply to the Editor." 
In their letter, Izzat and Yim essentially voice four 
criticisms of our results: first, that the transvalvular p es- 
sure drops that we report for mechanical prostheses are 
too high; second, that we should have taken measure- 
ments during exercise or after dobutamine infusion; third, 
that we should have investigated the dependence of 
patient-prosthesis mi match on cardiac output rather than 
body surface area; and fourth (and presumably as a 
corollary of the first and third criticisms), that our recom- 
mendation that 19 mm valves not be implanted in patients 
with body surface areas greater than 1.7 m 2 is irrelevant. 
Their first criticism is based on three points: a theoret- 
ical argument relating to the high-velocity central jet of 
bileaflet valves; the fact that we find no significant differ- 
ence between the transvalvular p essure drops of bileaflet 
valves and bioprostheses (which they believe to have 
higher transvalvular pressure drops); and comparison with 
the transvalvular p essure drops reported in three papers 
authored by, among others, Izzat. 
With regard to the first argument, we point out that, 
regardless of what the velocities of the lateral jets may be, 
that of the central jet is the result of a pressure that is a 
valid measure of ventricular effort and can be accurately 
calculated from the measured velocities (the value so 
calculated essentially does coincide with catheter mea- 
surements1). With regard to the second point, we note 
that bioprostheses do not necessarily have similar hemo- 
dynamics 2, 3; in all the small bioprostheses in our study the 
flaps were mounted outside the stent, and their hemody- 
namic performance is better than that of tilting disc valves 
and at least as good as that of bileaflet valves. 1-6 With 
regard to the third point, we frankly do not understand the 
transvalvular p essure drops reported in the papers they 
cite 7, 8 (e.g., mean transvalvular p essure drops of 3.12 _+ 
3.6 mm Hg for nine 21 mm St. Jude Medical valves [St. 
Jude Medical, Inc., St. Paul, Minn.], 4.87 ± 3.8 mm Hg for 
ten 21 mm CarboMedics valves [CarboMedics, Inc., Aus- 
tin, Tex.], and 8.1 ± 8.4 mm Hg for eight 19 mm 
CarboMedics valves), which are between one half and one 
sixth of the values habitually found, not only by us, but by 
numerous other groups. For example, De Paulis and 
associates 4 reported values of 20.1 ± 7.1 and 12.3 ± 3.4 
mm Hg, respectively, for 19 and 21 mm CarboMedics 
valves; Franzen and colleagues, 5 17.0 ± 5.6 and 18.0 ± 7.7 
mm Hg, respectively, for 21 mm CarboMedics and St. 
Jude Medical valves: and Ihlen.- Chambers. ~ and their 
coworkers. 17.1 ± 5.6 and 19.4 ~ 5.6 mm Hg, respectively, 
for 19 mm CarboMedics valves. 
In response to their second criticism, we have recently 
submitted for publication the exercise results obtained in 
the study that was mentioned in our article as still in 
progress. We do not believe that publication of the 
"disturbing" results obtained at rest with 19 mm valves 
should necessarily have awaited completion of the fuller 
studv. 
In response to their third criticism, transvalvular p es- 
sure drops are influenced by maw interrelated factors, 
including valve area. systolic volume (and hence Cardiac 
output), outflow tract anatomy, ventricular function, and 
body surface area. No correlation between transvalvular 
pressure drop and any single factor appears to be stable 
under variation of other factors. For example, in one of 
the papers by Izzat and others. 8 there was a correlation 
between transvalvular p essure drop and cardiac output 
and transvalvular p essure drop and body surface area for 
one prosthesis type but not for another: unpublished 
results of our own. for 19 mm valves but not for larger 
sizes, exhibit correlations of transvalvular p essure drop 
with body surface area both at rest and after exercise and 
correlation with cardiac output only after exercise. On the 
other hand, quite an uncontroversial correlation exists 
between body surface area and aortic root size, which is 
what determines the size of prosthesis that can be im- 
planted without a root enlargement procedure. 
In view of the foregoing, we believe it is unnecessary to 
reply explicitly to their fourth criticism. 
We incidentally point out what must surely be an error 
in two of Izzat's papers. 7's both of which report a cardiac 
output of only 2.8 L/min in their group of 10 patients with 
21 mm CarboMedics valves (of the value of 4.1 L/min they 
report for their 19 mm group). We also take this oppor- 
tunity to point out another unconvincing feature of the 
data reported in one of the papers by lzzat and others7: 
the finding that whereas the effective area of 19 mm 
CarboMedics valves was 1.37 = 0.53 cm 2. that of 21 mm 
vanes of the same type was only 1.20 ~ 0.62 cm 2. The 
problem there is not so much that the order of the mean 
values is the reverse of what it should logically be. but that 
this inversion is presumably the result of standard evia- 
tions that are much larger than those usually reported (0.1 
to 0.2 cm ~ for 19 mm valves1-6). One wonders whether 
these large standard eviations really reflect mainly inter- 
patient variation, especially inasmuch as no data on 
evaluator variability are given. 
To close, we reiterate our reservations a to the routine 
use of 19 mm prostheses and bioprostheses. The exercise 
results to which Izzat and Yim look forward, and whose 
recent submission for publication was mentioned earlier. 
show that the increase in transvalvular pressure drops 
across small valves during effort is. to say the least. 
alarming. 
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Myocardial protection of the hypoxic heart 
To the Editor: 
The study of Bolling and associates 1 on myocardial 
protection in normal and hypoxically stressed hearts in 
this Journal concluded that good myocardial protection is
independent of cardioplegic alcium concentration in 
nonhypoxic hearts and that hypoxic hearts are extremely 
sensitive to the cardioplegic calcium concentration. The 
authors lamented the absence of a clinically relevant 
hypoxic model. This is an important consideration, be- 
cause many children who undergo cardiac operations in 
the first year of life have cyanotic heart disease, and the 
myocardium may be chronically perfused with hypoxic 
blood. Clearly it would be desirable to alter current 
techniques of myocardial management during surgery to 
provide better myocardial protection for children with 
cyanotic ongenital heart disease and to further determine 
whether such techniques might also be applied to adults 
with acyanotic acquired heart disease. If the impact of 
prolonged periods of hypoxia on tolerance to subsequent 
ischemia could be elucidated, cardioprotection i  these 
patients could be better understood and improved. The 
model of acute hypoxia described by Bolling and col- 
leagues, ~which was originally described by Buckberg, 2 
Ihnken, 3 and their associates, does not allow for the 
development of adaptive mechanisms in response to 
chronic hypoxia that occur in children with cyanotic heart 
disease. In addition, it is unknown whether eoxygenation 
is a real source of cardiac dysfunction in the chronically 
hypoxic immature heart. Preexisting injury caused by 
acute hypoxia may be a prerequisite for reoxygenation 
injury in the studies described by Bolling's group. 1
Our laboratory has developed a rabbit model of hypoxia 
from birth that simulates the essential characteristics of
cyanotic heart disease: decreased arterial oxygen levels, 
polycythemia, increased right ventricular mass, decreased 
weight gain, and overall failure to thrive. 4 We have 
demonstrated that hypoxia from birth increases the toler- 
ance of the heart to ischemia compared with that of 
age-matched normoxic ontrol subjects. 4 The mechanism 
for adaptation to prolonged hypoxia that confers in- 
creased tolerance to subsequent myocardial ischemia is 
currently unknown. 
We have also examined the calcium content of St. 
Thomas' Hospital II cardioplegic solution and found in 
our model that the existing calcium content of 1.2 mmol/L 
is suboptimal to protect he ischemic immature myocar- 
dium. Optimal myocardial protection occurred with a 
calcium concentration of 0.4 mmo!/L in hearts chronically 
hypoxic from birth 5 and 0.3 mmol/L in hearts normoxic 
from birth. 6 These previously published ata may place in 
perspective the study by Bolling and coworkers, confirm- 
ing their hypothesis of hypocalcemic cardioplegia being 
superior to normocalcemic cardioplegia in protection of 
immature myocardium. The response, however, of imma- 
ture myocardium to acute versus chronic hypoxia before 
reoxygenation, with and without surgical ischemia, is 
speculative because neither we nor Bolling and his asso- 
ciates addressed this particular issue. 
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